1-9 of 9
Judah Friedman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Clinical Trials & Observations
Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason M. Melear, Ian W. Flinn, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Matthew Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte A. Yimer, Miguel Islas-Ohlmayer, Ameet Patel, Leland Metheny, Asad Dean, Vishal Rana, Mitul D. Gandhi, John S Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood blood.2024024681.
https://doi.org/10.1182/blood.2024024681
Published: 2024
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte A. Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Scott Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Chris Yasenchak
Journal: Blood
Blood (2023) 142 (Supplement 1): 608.
https://doi.org/10.1182/blood-2023-173972
Published: 2023
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2022) 140 (Supplement 1): 763–765.
https://doi.org/10.1182/blood-2022-156553
Published: 2022
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Matthew R. Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Amanda L. Gillespie-Twardy, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2021) 138 (Supplement 1): 2454.
https://doi.org/10.1182/blood-2021-147891
Published: 2021
Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress)

Ian W. Flinn, Judah Friedman, Linda Ho, Hun Ju Lee
Journal: Blood
Blood (2021) 138 (Supplement 1): 1369.
https://doi.org/10.1182/blood-2021-152231
Published: 2021
Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2836.
https://doi.org/10.1182/blood-2019-122969
Published: 2019
Journal Articles

Gene Expression Profiles (GEP) To Predict at Least Very Good Partial Response to Velcade, Doxil, and Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma.

Malathi Hari, James MacDonald, Judah Friedman, Tara Kendall, George Mulligan, Andrzej Jakubowiak
Journal: Blood
Blood (2007) 110 (11): 1489.
https://doi.org/10.1182/blood.V110.11.1489.1489
Published: 2007
Journal Articles

High Rate of Complete and near Complete Responses (CR/nCR) after Initial Therapy with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Further Increased after Autologous Stem Cell Transplantation (ASCT).

Andrzej J. Jakubowiak, MD, PhD, Ammar Al-Zoubi, MD, Tara Kendall, PA-C, Judah Friedman, MD, Asra Ahmed, MD, Yasser Khaled, MD, Shin Mineishi, MD, Mark S. Kaminski, MD
Journal: Blood
Blood (2006) 108 (11): 3093.
https://doi.org/10.1182/blood.V108.11.3093.3093
Published: 2006
Journal Articles

Combination Therapy with Velcade, Doxil, and Dexamethasone (VDD) for Patients with Relapsed/Refractory Multiple Myeloma (MM).

Andrzej J. Jakubowiak, MD, PhD, Lindsey Brackett, PA-C, Tara Kendall, PA-C, Judah Friedman, MD, Mark S. Kaminski, MD
Journal: Blood
Blood (2005) 106 (11): 5179.
https://doi.org/10.1182/blood.V106.11.5179.5179
Published: 2005